Molecular and clinical implications of CHD1 loss and SPOP mutations in advanced prostate cancer.

被引：1
|
作者：
Rescigno, Pasquale
Boysen, Gunther
Rodrigues, Daniel Nava
Seed, George
Dolling, David
Riisnaes, Ruth
Crespo, Mateus
Bianchini, Diletta
Sumanasuriya, Semini
Figueiredo, Ines
Christova, Rossitza
Gil, Veronica
Goodall, Jane
Sharp, Adam
Rubin, Mark A.
Yuan, Wei
Barbieri, Christopher
Mateo, Joaquin
Carreira, Suzanne
De Bono, Johann S.
机构：
[1] Inst Canc Res, Sutton, Surrey, England
[2] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England
[3] Inst Canc Res, Clin Trials & Stat Unit, London, England
[4] Univ Bern, Bern, Switzerland
[5] Weill Cornell Med Coll, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.5064
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5064
引用
收藏
页数：1
相关论文
共 50 条
  • [31] CHD1 deletion stabilizes HIF1a to promote angiogenesis and glycolysis in prostate cancer
    Wang, Yu-Zhao
    Qian, Yu-Chen
    Yang, Wen-Jie
    Ye, Lei-Hong
    Guo, Guo-Dong
    Lv, Wei
    Huan, Meng-Xi
    Feng, Xiao-Yu
    Wang, Ke
    Yang, Zhao
    Gao, Yang
    Li, Lei
    Chen, Yu-Le
    ASIAN JOURNAL OF ANDROLOGY, 2023, 25 (02) : 152 - 157
  • [32] Identification of novel CHD1-associated collaborative alterations of genomic structure and functional assessment of CHD1 in prostate cancer
    Liu, W.
    Lindberg, J.
    Sui, G.
    Luo, J.
    Egevad, L.
    Li, T.
    Xie, C.
    Wan, M.
    Kim, S-T
    Wang, Z.
    Turner, A. R.
    Zhang, Z.
    Feng, J.
    Yan, Y.
    Sun, J.
    Bova, G. S.
    Ewing, C. M.
    Yan, G.
    Gielzak, M.
    Cramer, S. D.
    Vessella, R. L.
    Zheng, S. L.
    Gronberg, H.
    Isaacs, W. B.
    Xu, J.
    ONCOGENE, 2012, 31 (35) : 3939 - 3948
  • [33] Identification of novel CHD1-associated collaborative alterations of genomic structure and functional assessment of CHD1 in prostate cancer
    W Liu
    J Lindberg
    G Sui
    J Luo
    L Egevad
    T Li
    C Xie
    M Wan
    S-T Kim
    Z Wang
    A R Turner
    Z Zhang
    J Feng
    Y Yan
    J Sun
    G S Bova
    C M Ewing
    G Yan
    M Gielzak
    S D Cramer
    R L Vessella
    S L Zheng
    H Grönberg
    W B Isaacs
    J Xu
    Oncogene, 2012, 31 : 3939 - 3948
  • [34] SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity
    Boysen, Gunther
    Rodrigues, Daniel N.
    Rescigno, Pasquale
    Seed, George
    Dolling, David
    Riisnaes, Ruth
    Crespo, Mateus
    Zafeiriou, Zafeiris
    Sumanasuriya, Semini
    Bianchini, Diletta
    Hunt, Joanne
    Moloney, Deirdre
    Perez-Lopez, Raquel
    Tunariu, Nina
    Miranda, Susana
    Figueiredo, Ines
    Ferreira, Ana
    Christova, Rossitza
    Gil, Veronica
    Aziz, Sara
    Bertan, Claudia
    de Oliveira, Flavia M.
    Atkin, Mark
    Clarke, Matthew
    Goodall, Jane
    Sharp, Adam
    MacDonald, Theresa
    Rubin, Mark A.
    Yuan, Wei
    Barbieri, Christopher E.
    Carreira, Suzanne
    Mateo, Joaquin
    de Bono, Johann S.
    CLINICAL CANCER RESEARCH, 2018, 24 (22) : 5585 - 5593
  • [35] Clinical impact of mutations in driver oncogenes and TP53/RB1 in advanced prostate cancer.
    Hammer, Liat
    Rebernick, Ryan
    McFarlane, Matthew
    Westbrook, Thomas
    Hazime, Munna
    Hammoud, Tanya
    Chiu, Pin-en
    Xavier, Owens
    Wu, Yi-Mi
    Robinson, Dan R.
    Spratt, Daniel Eidelberg
    Alva, Ajjai Shivaram
    Jackson, William C.
    Reichert, Zachery R.
    Alumkal, Joshi J.
    Chinnaiyan, Arul
    Cieslik, Marcin
    Dess, Robert Timothy
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [36] Clinical and molecular features of ATM and BRCA2 mutations in metastatic prostate cancer.
    Shi, Xiaolei
    Hwang, Justin
    McGrath, Julie
    Bergom, Hannah E.
    Day, Abderrahman
    Toye, Eamon
    Passow, Rachel
    Tape, Sydney
    Makovec, Allison
    Lozada, John R.
    Ryan, Charles J.
    Carneiro, Benedito A.
    McKay, Rana R.
    Nabhan, Chadi
    Korn, W. Michael
    Antonarakis, Emmanuel S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [37] Loss of CHD1 causes DNA repair defects and enhances prostate cancer therapeutic responsiveness (vol 17, pg 1609, 2016)
    Kari, Vijayalakshmi
    Mansour, Wael Yassin
    Raul, Sanjay Kumar
    Baumgart, Simon J.
    Mund, Andreas
    Grade, Marian
    Sirma, Huseyin
    Simon, Ronald
    Will, Hans
    Dobbelstein, Matthias
    Dikomey, Ekkehard
    Johnsen, Steven A.
    EMBO REPORTS, 2018, 19 (10)
  • [38] The role of chromodomain helicase DNA binding protein 1 (CHD1) in promoting an invasive prostate cancer phenotype
    Kareddula, Aparna
    Medina, Daniel J.
    Petrosky, Whitney
    Dolfi, Sonia
    Tereshchenko, Irina
    Walton, Kelly
    Aviv, Hana
    Sadimin, Evita
    Tabakin, Alexandra L.
    Singer, Eric A.
    Hirshfield, Kim M.
    THERAPEUTIC ADVANCES IN UROLOGY, 2021, 13
  • [39] MAP3K7 Loss Drives Enhanced Androgen Signaling and Independently Confers Risk of Recurrence in Prostate Cancer with Joint Loss of CHD1
    Jillson, Lauren K.
    Rider, Leah C.
    Rodrigues, Lindsey U.
    Romero, Lina
    Karimpour-Fard, Anis
    Nieto, Cera
    Gillette, Claire
    Torkko, Kathleen
    Danis, Etienne
    Smith, Elizabeth E.
    Nolley, Rosalie
    Peehl, Donna M.
    Lucia, M. Scott
    Costello, James C.
    Cramer, Scott D.
    MOLECULAR CANCER RESEARCH, 2021, 19 (07) : 1123 - 1136
  • [40] Obesity and prostate cancer. Role of adipocytokines and clinical implications
    Hoda, M. R.
    Mohammed, N.
    Theil, G.
    Fischer, K.
    Fornara, P.
    UROLOGE, 2012, 51 (09): : 1253 - +
12345